We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.04 | -3.02% | 33.35 | 33.50 | 32.825 | 33.24 | 13,747,891 | 01:00:00 |
From Nov 2021 to Nov 2024
By Anthony O. Goriainoff
GSK PLC said Tuesday that Japan's Ministry of Health, Labour and Welfare has accepted its regulatory application for its shingles-prevention treatment, Shingrix, so that it is used in adults age 18 and older who are at increased risk.
The U.K. pharmaceutical company, formerly known as GlaxoSmithKline, said Shingrix has already been approved in the country for adults age 50 and older.
The company said Shingrix's application was based on six clinical trials in patients 18 and older who had undergone recent blood-forming cells (stem cell)transplantation, kidney transplant, or have blood cancer, solid tumors or HIV.
"Shingrix is also recommended in the U.S. by the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices as the preferred vaccine for the prevention of shingles and related complications for immunocompetent adults aged 50 years and older," the company said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
June 28, 2022 02:34 ET (06:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
